Weed for sale: Ohio goes legal ??

Welcome back to your weekly Monday morning round up of the most important cannabis and psychedelics industry headlines you need to know. Let's get started.

The top 7 cannabis stories you need to know ??

1. Curaleaf ($CURA ) gets conditional approval from TSX to list subordinate voting shares, pending satisfaction of customary listing conditions.
2. Veterans urge Biden for prompt marijuana scheduling review completion and broader reform while countering misinformation.
3. Bonjour! The French government grants temporary authorization for medical cannabis in hospitals with a potential for indefinite renewal, aiming to define pricing and criteria.
4. Japan's parliament lifts ban on cannabis-derived medicines, primarily to enable treatment for intractable epilepsy, while maintaining strict penalties for narcotic use.
5. DEA warns Georgia pharmacies against dispensing medical cannabis due to federal illegality, restricting distribution to Schedules II-V of the Controlled Substances Act.
6. Six governors (Colorado, Illinois, New York, New Jersey, Maryland and Louisiana) urge President Biden to reschedule marijuana to Schedule III by year-end, citing economic benefits, public health, and aligning with public opinion.
7. Ohio's GOP-controlled Senate surprisingly passes bill expanding marijuana legalization, allowing immediate sales, home cultivation, and record expungement.

Read the full stories here.

The top 5 psychedelics stories you need to know ??

1. Cybin Inc . receives U.S. patent 11,834,410 supporting CYB003 deuterated psilocybin analog program, offering exclusivity until 2041 with claims covering therapeutic treatments.
2. 强生公司 highlights neuroscience's key role in revenue goals, focusing on two drugs, seltorexant and aticaprant, currently in phase 3 trials, Major Depressive Disorder treatments anticipated to generate at least $1 billion each by 2030.
3. The AdvisorShares Psychedelics ETF ($PSIL ) showed a slight increase of 0.75%, while biopharma indices experienced gains of 2.15% and 1.04%, respectively. Conversely, the NASDAQ 100 and S&P 500 fell by 0.86% and 0.99% amidst market volatility.
4. A recent clinical trial published by the American Medical Association indicates that psilocybin-assisted psychotherapy demonstrates potential efficacy and safety in treating bipolar II disorder. Out of 12 patients involved, the trial showed significant reductions in diagnostic measures over a 12-week study period.
5. Congressional lawmakers, in agreement on the defense bill, have included provisions to fund psychedelics studies for military service members, championed by Rep. Morgan Luttrell, while opting not to pursue a medical cannabis pilot program for veterans.

Here's how some popular psychedelic stocks are faring this week:

Read the full stories here.

Catching up on Trade To Black Podcast ???

Last week, Shadd Dales , Anthony Varrell , and Benjamin A. Smith talked about everything from the big New York announcement allowing several brands to initiate adult-use wholesale distribution, including The Cannabist Company, Curaleaf , and PharmaCann Inc , to name a few, Bitcoin's massive surge earlier in the beginning of the week, and more.

Catch up in the videos below, and be sure to subscribe so you never miss another one.

Trade To Black airs on The Dales Report and Benzinga 's YouTube channels at 4:10 PM EST every Monday, Wednesday, and Friday.

Don't miss any of our episodes. Subscribe now and hit the notification bell to know every time we go live.

Want more of The Dales Report? Check us out on Twitter (X) and Instagram , and subscribe to our weekly email newsletter for an even more in-depth dive on the latest cannabis, psychedelics, and crypto business and investment news.

Hey, brands and companies: Want to be seen by our audience of nearly 40,000 highly engaged psychedelics, cannabis, and stock market enthusiasts across all of our platforms?

Email [email protected] for info on sponsorships and pricing. Our weekly email newsletter has an open rate average of 33% (that's pretty high, and we're not just saying that.)

Let's get your message heard, and, most importantly, heard by the right people.